

## Index

Page numbers in *italic* refer to figures.

Page numbers in **bold** refer to tables.

### a

- abacavir 156–158
- abscesses, diverticulitis 275–276
- absolute risk reduction 6
- academic detailing, on prescribing
  - behavior 240
- accountable justification, antimicrobial
  - stewardship 243
- aciclovir, *see* acyclovir
- acid-fast bacilli 89
- Acinetobacter* (spp.), ICU environments 223
- ACTG 5142 (trial of antiretroviral
  - therapy) 158
- actoxumab 104
- acute prosthetic joint infection 27, 29
- acyclovir
  - encephalitis 65
  - genital herpes 136, 137
  - orolabial herpes 162
  - varicella zoster post-exposure
    - prophylaxis 283
- adefovir, hepatitis B and 184
- adenosine deaminase testing,
  - tuberculosis 90
- adenosine triphosphate, assessment of
  - cleaning 223
- adherence, *see* compliance
- admission to hospital
  - community-acquired pneumonia 74
  - pelvic inflammatory disease 134
  - urinary tract infections 119
- adverse events
  - on antiretroviral therapy adherence 159
  - contact precautions and 221
  - fluoroquinolones 76–77
- Aeromonas hydrophila*, antibiotics 17
- Africa
  - cryptococcal meningitis 164
  - Pneumocystis jiroveci* prophylaxis 161
- AIDS dementia complex 167
- alcohol, *see* ethanol
- alkalization of urine 112
- allocation, concealment 5
- alpha-defensin, prosthetic joint infection and 27
- AmBisome (liposomal amphotericin),
  - cryptococcal meningitis 163
- aminoglycosides 43
  - neutropenic fever syndrome 259
  - urinary tract infections 120
- amoxicillin
  - Chlamydia trachomatis* 133
  - infective endocarditis 47
  - urinary tract infections 111
- amoxicillin/clavulanate, urinary tract
  - infections 111
- amphotericin B, cryptococcal meningitis
  - 163–165
- ampicillin
  - infective endocarditis 42, 47
  - meningitis 57, 58
- anaphylaxis, HPV vaccines 140
- animal bites 19–20
  - rabies 20, 62–63
- anogenital warts 138–139

- antibiograms, as outcome measures **239**
- antibiotics, *see also* antimicrobial stewardship
  - animal bites 20
  - carbuncles 14
  - cellulitis 15
  - central line-associated bloodstream infections 208–209
  - for *Clostridium difficile* 100–103
  - community-acquired pneumonia 75–77
  - diabetic ulcers 19
  - diverticulitis 275
  - healthcare-associated pneumonia 83–84
  - impetigo 13
  - infective endocarditis 41–43
    - prophylaxis 46, 47
    - after surgery 45–46
  - meningitis 57
  - monotherapy vs combination therapy 236
  - necrotizing fasciitis 17, 271
  - neutropenic fever syndrome 256, 258–261
  - osteomyelitis 32–33
  - peri-operative prophylaxis 228–230
  - prostatitis and 117–118
  - prosthetic joint infection 29, 30
  - resistance, *see* antimicrobial resistance
  - sepsis 204
  - septic arthritis 25
  - surgical site infections 270
  - syphilis, pregnancy 135
  - unnecessary treatment 109, 235–236
  - urinary tract infections 109–111, 117–118
    - duration of response 120
    - prevention 114–115
    - severe 119–121
    - speed of response 121
  - ventilator-associated pneumonia 206–207
- antibody testing, hepatitis C 185
- anticancer therapy, fever 252
- antigen testing, tuberculosis 90
- antigen/antibody combination testing, HIV 150
- antigenic drift and shifts, influenza 194
- antimicrobial resistance 235, *see also*
  - multidrug-resistant pathogens;
  - multidrug-resistant TB
- fluoroquinolones 132
- neutropenic fever syndrome 262–263
- Escherichia coli* ST131 110
- urinary tract infections 111, 112, 120–121
- antimicrobial stewardship 77, 235–251
  - appropriateness of therapy, as outcome measure **239**
  - assessment of programs 237–238
  - interventions for 239–243
  - measuring outcome **239**
  - organization of programs 243
  - prospective audit and feedback 239–240
  - suggested alternatives 243
- anti-NMDA receptor antibody encephalitis 61
- antiretroviral therapy 156–161, *see also*
  - highly active antiretroviral therapy
  - early HIV 150–151
  - toxicity 160
    - liver 154, 160
  - tuberculosis and 91
- antiseptic soap 218
- antiseptics
  - central venous catheters 209–210
  - joints and 25
- arboviruses, encephalitis 62, 63, **64**, 65
- arthritis, septic 23–26
- arthroplasty, infection 26–30
- arthroscopy, septic arthritis after 24
- aseptic failure, prosthetic joint surgery 27
- Asian, hepatitis B 183
- aspiration (therapeutic)
  - chancroid 137
  - lymphogranuloma venereum 137–138
  - prosthetic joint infection 27
- aspiration (to lungs), prevention 207
- asymptomatic bacteriuria 108, 110, 113–114, 116, 118
- asymptomatic HIV 150–151
- atazanavir 156
- atovaquone, *P. jiroveci* pneumonia 156, 161
- atypical pathogens, community-acquired pneumonia, treatment 76
- audit, *see* prospective audit and feedback
- autonomic neuropathy, urinary tract infections 112
- azithromycin
  - chancroid 137
  - Chlamydia trachomatis* 133
  - community-acquired pneumonia 77
  - granuloma inguinale 138
  - infective endocarditis 47
  - lymphogranuloma venereum 137–138

- Mycobacterium avium* complex 165–167
- Mycoplasma genitalium* 133
- syphilis 135
- treatment of sexual partners 139
- b**
- bacille Calmette–Guérin (BCG) 93–94
- back pain, urinary tract infections **108**
- bacteremia
  - febrile neutropenic episodes 257
  - septic arthritis 23
  - urinary tract infections 119
- bacteriuria 108, 110, 113–114, 116, 118
- baseline genotypic resistance testing,
  - HIV 151–152
- bedaquiline 92
- before-and-after data 2
- behavioral interventions
  - antimicrobial stewardship 242–243
  - sexually transmitted infections and 140
- Benefits of Universal Glove and Gown trial 220
- benzathine penicillin
  - impetigo 13
  - syphilis 134–135
  - treatment of partners 139
- beta-D-glucan, *P. jiroveci* pneumonia 155
- β-lactam antibiotics
  - allergy 261–262
  - cellulitis 15
  - community-acquired pneumonia 76
  - extended-spectrum resistance 121, 262, 263
  - monotherapy 236
  - neutropenic fever syndrome 259–260
  - urinary tract infections 111
- bezlotoxumab 104
- BHIVA grading, antiretroviral therapy 156
- bilirubin, SOFA score **202**
- biofilms 26
  - antibiotic treatment 30
- biologic immunosuppressive therapy,
  - tuberculosis and 88
- biomarkers, prosthetic joint infection 27
- biopsies
  - osteomyelitis 31–32
  - periprosthetic infections 28
- bites, *see* animal bites
- bladder, neurogenic, urinary tract
  - infections 115
- bladder outflow obstruction, men 116
- bleach 224
- blood, exposure of healthcare workers
  - 280–282
- blood cultures
  - central line-associated bloodstream
    - infections 208
  - community-acquired pneumonia 75
  - febrile neutropenic episodes 254–255
  - infective endocarditis 38
  - meningitis 56
  - septic arthritis 24
  - urinary tract infections 119
- bloodstream infections, *see also* sepsis
  - central line-associated 207–210
  - antibiotic-resistant 262
- body fluids, exposure of healthcare
  - workers 280–282
- body washing, chlorhexidine 221, 227
- bone, *see* osteomyelitis
- Bourbon virus, encephalitis 62
- broad spectrum antibiotics
  - healthcare-associated pneumonia 83
  - neutropenic fever syndrome 259, 260
- bronchitis, inappropriate antimicrobial
  - use 237
- bullous impetigo 13
- bundled interventions, surgical site
  - infections 228–230
- c**
- Caesarean section, herpes simplex virus 137
- Canadian Triage Assessment Scores 254
- cancer patients, *see* neutropenic fever
  - syndrome
- candidiasis
  - bloodstream infections 209
  - HIV infection 165
  - infective endocarditis 38
- CAPITA trial, pneumococcal vaccine 78
- carbapenemase genes, *E. coli* ST131 110
- carbapenems, neutropenia and 260, 263
- carbon dioxide laser therapy, genital
  - warts 139
- carbuncles 13–14
- cardiac transplantation, antibiotic
  - prophylaxis **47**
- cardiovascular disease, antiretroviral
  - therapy 157

- CD4 counts
  - pathogens associated **164**
  - starting ART 150–151
- cefazolin
  - infective endocarditis **42, 47**
  - surgical site infection prevention 228
- cefipime, neutropenia and 260
- cefixime, urinary tract infections 120
- cefotaxime, meningitis **58**
- cefoxitin, pelvic inflammatory disease 134
- ceftazidime
  - meningitis **58**
  - neutropenia and 260
- ceftibuten, urinary tract infections 120
- ceftriaxone
  - cellulitis 15
  - chancroid 137
  - infective endocarditis **42, 47**
  - meningitis **58**
  - resistance 121
  - syphilis 135
  - urinary tract infections 120
- cefuroxime, surgical site infection
  - prevention 228
- cell cytotoxin assay, *C. difficile* 100
- cellulitis 14–16
  - necrotizing fasciitis vs 271
- central line-associated bloodstream
  - infections 207–210
  - antibiotic-resistant 262
- central venous pressure (CVP),
  - sepsis 203
- cephalexin, infective endocarditis **47**
- cephalosporins, *see also specific drugs*
  - necrotizing fasciitis 17
- Cepheid Xpert MTB/RIF test 89, 153
- cerebrospinal fluid
  - encephalitis 64, 65
  - herpes simplex virus, PCR 130
  - meningitis 56
  - pressure, cryptococcal meningitis 165
  - progressive multifocal
    - leukoencephalopathy 167–168
  - syphilis 131, 134, 135
- cerebrovascular imaging, infective
  - endocarditis 43–44
- cervicitis 128
  - mucopurulent 132–134
- chancre 129
- chancroid 129
  - laboratory testing 130
  - management 137
- Charcot foot 18
- chemical depilation, surgical site infections
  - and 226
- chemotherapy, fever 252
- chest X-rays
  - community-acquired pneumonia 73–74
  - tuberculosis 90
- chickenpox 283
- Chinese, hepatitis B 183
- Chlamydia pneumoniae*, community-
  - associated pneumonia 83
- Chlamydia trachomatis* 127
  - condoms and 139
  - laboratory testing 129–130
  - lymphogranuloma venereum 130
  - management 132–134
  - pelvic inflammatory disease 134
  - screening 129
- chlorhexidine
  - central venous catheters 209
  - oral hygiene 207
  - scrub 227–228
  - universal body washing 221
- chronic hepatitis B 183
- chronic prosthetic joint infection 27, 29
- chronic suppressive therapy, HSV 136, 137
- ciprofloxacin
  - chancroid 137, 138
  - Chlamydia trachomatis* 133
    - after cystoscopy 114
  - granuloma inguinale 138
  - with meropenem 236
  - prosthetic joint infection 30
  - pyelonephritis, duration of treatment 236
  - urinary tract infections 111, 117, 118, 120
- cirrhosis, hepatitis C 186–187, **188**
- clarithromycin, *Mycobacterium avium*
  - complex HIV 165–167
- clean wounds, defined **229**
- clean-contaminated wounds, defined **229**
- cleaning, environmental 222, 223
- clench fist injury 19
- clindamycin
  - infective endocarditis **47**
  - necrotizing fasciitis 17
  - Pneumocystis jiroveci* pneumonia 156

- clinical importance, statistical significance  
vs 6
- clinical outcomes, antimicrobial  
stewardship 237, **239**
- clinically documented infections (CDI),  
neutropenic fever 256, 257
- clipping (hair removal), surgical site infections  
and 226
- clofazimine, *Mycobacterium avium*  
complex 166
- Clostridium* (spp.), antibiotics 17
- Clostridium difficile* 99–106
  - antimicrobial stewardship and 77
- clotrimazole suppositories, trichomoniasis  
and 134
- cluster randomization 6
- coagulase negative staphylococci, infective  
endocarditis 38
- cobicistat 156
- cohort studies 7
  - infective endocarditis 44–46
- colectomy, diverticulitis 276
- colitis
  - cytomegalovirus infection 167
  - pseudomembranous 100
- colonization
  - central venous catheters 207
  - upper airways 206
- colonoscopy, diverticulitis 275
- combination therapy, monotherapy vs,  
neutropenic fever 236
- common cold, inappropriate antimicrobial use  
236–237
- community-acquired pneumonia 73–80
- community-acquired respiratory viruses,  
neutropenic fever syndrome 255,  
257, 259
- compliance
  - antimicrobial stewardship 237
  - antiretroviral therapy 159–161
  - hand hygiene 219
- complicated *C. difficile* infection  
(cCDI) 99
  - antibiotics for 101
- complicated urinary tract  
infections 118–121
- computed tomography
  - community-acquired pneumonia 74
  - diverticulitis 275
- ECG-gated angiography, infective  
endocarditis 41
- meningitis 56
- osteomyelitis 32
- septic arthritis 25
- concealment, allocation 5
- concentration, sputum, tuberculosis 153
- condoms 139
- confidence intervals 5–6
- confounding by indication 4
- confounding factors 4–5
- congenital heart disease, antibiotic  
prophylaxis **47**
- conjugated vaccines
  - Hib 58
  - pneumococcal 78
- CoNS (coagulase negative staphylococci),  
infective endocarditis 38
- contact precautions 220–222
- contaminated wounds, defined **229**
- contamination
  - hands 218–219
  - ICU environments 222–224
  - urine 109
- contiguous osteomyelitis 31
- continuous low-dose prophylaxis, urinary tract  
infections 114–115
- contraceptives 139
- core temperature, in surgery 225
- corticosteroids
  - community-acquired pneumonia 77
  - influenza and 195
  - meningitis 57–58
  - Pneumocystis jiroveci* pneumonia 155–156
  - sepsis 205
  - tuberculosis 91
- cost of therapy, as outcome measure **239**
- costovertebral angle tenderness, urinary tract  
infections **108**
- costs
  - central line-associated bloodstream  
infections 207
  - urinary tract infections 107
- co-trimoxazole, *see* trimethoprim/  
sulfamethoxazole
- cough, influenza 193–194
- counseling, sexually transmitted infections  
and 140
- Coxiella* (spp.), infective endocarditis 39

- CPCRA 058 (FIRST trial), antiretroviral therapy 158
- cranberry juice 114
- C-reactive protein
- osteomyelitis 31
  - septic arthritis 24
- creatinine, SOFA score **202**
- critical care 201–215
- cryoglobulinemia 186
- cryptococcal meningitis 163–165
- crystal-induced arthritis 24
- culture, *see also* blood cultures
- Chlamydia trachomatis* 129
  - herpes simplex virus 130
  - Neisseria gonorrhoeae* 129
  - periprosthetic 28
  - surgical site infections 270
  - Trichomonas vaginalis* 130
  - tuberculosis 89–90, 153
  - urinary tract infections 108–110, 112–113, 116
- culture-negative endocarditis 39
- culture-negative septic arthritis 24
- CURB-65 score 74
- cure, as outcome measure, antimicrobial stewardship **239**
- curettage, *see also* debridement
- diabetic ulcers 18
- cystitis
- antibiotics 111
  - after asymptomatic bacteriuria 113
- cystoscopy, asymptomatic bacteriuria after 114
- cytomegalovirus
- encephalitis 63, **64**
  - HIV infection 167
- cytotoxic therapy, fever 252
- d**
- daclatasvir 187
- dapsone prophylaxis
- Pneumocystis jiroveci* 161
  - toxoplasmosis 162
- daptomycin, infective endocarditis **42, 43**
- darunavir (DRV) 156, 158
- dasabuvir **188**
- days of therapy, as outcome measure, antimicrobial stewardship **239**
- debridement, *see also* curettage
- for osteomyelitis 32
  - source control for sepsis 204
- decolonization, nasal 227
- deferred therapy, HIV 150, 151, 154
- defervescence, neutropenic fever syndrome 260–261
- defined daily dose, as outcome measure **239**
- delaminid 92
- delay of therapy, urinary tract infections 109
- depilation, surgical site infections and 226
- design of studies, antimicrobial stewardship 237–238
- dexamethasone, meningitis 57–58
- diabetes
- foot infections 18–19
  - surgical site infections 224–225
  - urinary tract infections 112, 118
- diagnosis, evidence-based 3–4
- diarrhea, *Clostridium difficile* 99–100
- didactic education, antimicrobial stewardship 241
- diet, diverticular disease 274
- dipstick testing, urine 107–109, 118
- Direct Acting Antivirals, hepatitis 186, 187
- direct observation, hand hygiene 219
- directly observed treatment, short course, tuberculosis 91
- dirty-infected wounds, defined **229**
- diverticulitis, acute 273–276
- DNA HBV vaccines 281
- DNA sequencing, infective endocarditis 39
- dog bites 19, 20
- dolutegravir (DTG) 156, 158–160
- donovanosis 129
- laboratory testing 131
  - management 138
- doxycycline
- Chlamydia trachomatis* 133
  - Clostridium difficile* and 77
  - granuloma inguinale 138
  - lymphogranuloma venereum 137–138
  - pelvic inflammatory disease 134
  - sypilis 135
- drainage
- abscesses, diverticulitis 275–276
  - chancroid 137
  - post-operative infections 270
- dressings, diabetic foot infections 19

- drug susceptibility testing, tuberculosis 89–91
- drug-drug interactions, HAART 158–159
- drug-resistant TB 91–92, *see also* multidrug-resistant TB
- drug-resistant HIV 151–152
- drug-resistant pathogens, *see* antimicrobial resistance; multidrug-resistant pathogens
- Duke Criteria, infective endocarditis 39–41
- duration of treatment, *see also* length of hospital stay
  - community-acquired pneumonia 77
  - neutropenic fever syndrome 260–261
  - as outcome measure, antimicrobial stewardship **239**
  - pyelonephritis, ciprofloxacin 236
- dysuria **108**
- e**
- early goal-directed therapy, sepsis 203
- Eastern equine encephalitis (EEE) 63
- echocardiography, infective endocarditis 39
- education, on prescribing behavior 239–241
- efavirenz 156–158
- effusions, septic arthritis 24
- eflornithine, *P. firoveci* pneumonia 156
- Eikenella corrodens* 20
- elastography, liver 187
- elbasvir **188**
- electrocardiogram-gated multidetector CT angiography, infective endocarditis 41
- electroencephalography, encephalitis 65
- elvitegravir 156
- embolism, infective endocarditis 38, 43–45
- emtricitabine 156–158, 281
- encephalitis 60–66
  - preventive therapy 66
- End TB Strategy 87
- endocarditis, *see* infective endocarditis
- endoscopy
  - Clostridium difficile* 100
  - diverticulitis 275
- endotracheal tubes, subglottic drainage 207
- entecavir, hepatitis B 184
- Enterobacteriaceae
  - antibiotic-resistant 262–263
  - healthcare-associated pneumonia 82
- enterococci, *see also* vancomycin-resistant *Enterococcus*
  - infective endocarditis 38, **42**
  - prosthetic joint infection 30
  - urinary tract infections 110, 120
- enteroviruses, encephalitis 63, 65–66
- environmental sources, multidrug-resistant pathogens 222–224
- epidemiology 1
  - central line-associated bloodstream infections 207
  - diverticular disease 274
  - encephalitis 60–61
  - hepatitis C 185
  - HIV 151–152
  - infective endocarditis 37–38
  - meningitis 53–55
  - sepsis 201
  - tuberculosis 87–88
  - ventilator-associated pneumonia 205
- Epstein–Barr virus, encephalitis 63, **64**
- erysipelas 14–16
- erythromycin
  - chancroid 137
  - Chlamydia trachomatis* 133
  - granuloma inguinale 138
  - impetigo 13
- Escherichia coli*
  - drug resistance 121
  - urinary tract infections 110
  - strain 83972 115
- ESS40013 study, antiretroviral therapy 157
- estrogens, urinary tract infection prevention 114
- ethambutol (ETH) 91, 92
  - HIV/TB co-infection 153–154
  - Mycobacterium avium* complex 166
- ethanol
  - central venous catheters 209–210
  - hand hygiene 218
- evidence, levels of 4, 7
- evidence-based diagnosis 3–4
- evidence-based infectious diseases, definition 1–2
- evidence-based medicine 1
- evidence-based treatment 4–7
- examination, neutropenic fever syndrome 254, **255**

expedited partner therapy, sexually transmitted infections 139  
 extended-spectrum  $\beta$ -lactamase resistance 121, 262, 263  
 extensively drug resistant TB 92  
 external validity 4

## f

failure of treatment, urinary tract infections 109  
 famciclovir  
   genital herpes 136, 137  
   orolabial herpes 162  
 fecal microbiota transplantation (FMT) 102, **103**  
 feedback, *see* prospective audit and feedback  
 fever  
   cancer patients 252, *see also* neutropenic fever syndrome  
   influenza 193–194  
   meningitis 55  
   post-operative 269–270  
   urinary tract infections, duration 121  
 Fibroscan 187  
 fibrosis, hepatitis C 187  
 fidaxomicin 101–102, **103**  
 fine-needle aspirate, necrotizing fasciitis 17  
 FIRST trial CPCRA 058, antiretroviral therapy 158  
 FLAMINGO study, antiretroviral therapy 158  
 floors, organisms 222  
 fluconazole  
   candidiasis 165  
   cryptococcal meningitis 163–165  
 flucytosine, cryptococcal meningitis 163–165  
 fluid therapy  
   neutropenic fever syndrome 255  
   sepsis 203  
 fluorescent markers, assessment of cleaning 223  
 fluorescent stains, tuberculosis 89  
 fluorescent treponemal antibody-absorption test, syphilis 131  
 $^{18}\text{F}$ -fluorodeoxyglucose PET/CT, infective endocarditis 41  
 fluoroquinolones 76–77  
   *Chlamydia trachomatis* 133  
   *Neisseria gonorrhoeae* 132

  resistance 121  
   urinary tract infections 111, 117, 120  
 follow-up, trials 5  
 fomites, and nosocomial infection 222  
 foot infections, diabetes 18–19  
 formulary restriction 241–242  
 Forte trial, antiretroviral therapy 157  
 foscarnet, cytomegalovirus infection 167  
 fosfomycin  
   prosthetic joint infection 30  
   urinary tract infections 111, 115  
 Fournier's gangrene 16  
 fourth-generation assays, HIV 149–150, 152  
 fourth-generation rapid tests, HIV 150  
 frequency of urination **108**  
 funding, antimicrobial stewardship 243  
 fungi, *see also* candidiasis  
   infective endocarditis 38–39  
   neutropenic fever syndrome 261  
 furuncles 13–14

## g

ganciclovir, CMV infection 167  
 gas gangrene 16  
 gastrointestinal disease, CMV infection 167  
 gastrointestinal symptoms  
   azithromycin 166  
   linezolid 83  
 gay men (MSM)  
   lymphogranuloma venereum 129  
   sexually transmitted infections, screening 129  
   urinary tract infections 116  
 generalizability 4  
 genital ulcer disease 128–129  
   early HIV 149  
   herpes simplex virus 136–137  
 genital warts 138–139  
 genotypes, *see also* baseline genotypic resistance testing  
   hepatitis B 184  
   hepatitis C 185, **188**  
   hepatitis E 189  
 gentamicin  
   infective endocarditis **42**, 43  
   septic arthritis 25  
 Global Plan to Stop TB 87  
 glomerulonephritis, hepatitis C 186

glucose  
  cerebrospinal fluid 56  
  surgical site infections 224–225, 230  
glutamate dehydrogenase, *C. difficile* 100  
glycopeptides, *see also* vancomycin  
  neutropenic fever syndrome 259–260  
gonorrhea, *see also* *Neisseria gonorrhoeae*  
  condoms and 139  
  incidence 127  
  management 132  
Gram stain  
  community-acquired pneumonia 75  
  meningitis 56  
Gram-negative bacteria  
  antibiotic-resistant 262–263  
  central line-associated bloodstream  
    infections 209  
  healthcare-associated pneumonia 83  
  meningitis 57, **58**  
  septic arthritis 24  
  urinary tract infections 110, 117  
  ventilator-associated pneumonia 206  
granulocytic immunodeficiency 251–252  
granuloma inguinale, management 138  
grazoprevir **188**  
group A streptococcus, necrotizing  
  fasciitis 16–18, 271

**h**

*Haemophilus ducreyi* 130  
*Haemophilus influenzae*  
  community-acquired pneumonia 75  
  meningitis 55, 58  
Hain MTBDRplus assay 153  
hair removal, surgical site infections and 226  
hand hygiene 217–219, 279  
  enhanced 221  
  environmental cleaning *vs* 222  
  influenza 197  
hazard ratio 5  
headache, meningitis 55  
healthcare workers (HCW)  
  hand contamination 218  
  infections in 279–288  
healthcare-associated infective  
  endocarditis 38  
healthcare-associated pneumonia 81–86  
healthcare-associated VZV infection 283–284  
heart failure, infective endocarditis 38

hematogenous osteomyelitis 31  
hematogenous seeding  
  prosthetic joint infection 27  
  septic arthritis 23  
hematuria **108**  
hemodialysis, hepatitis B vaccination 183  
hemodynamic resuscitation, sepsis 203  
hepatitis 183–193  
  hepatitis A 181, **182**  
  hepatitis B 182–184  
    antiretroviral therapy, HIV 157, 160  
    exposure of healthcare workers 281  
    hepatitis C with 187–189  
    hepatitis D and 189  
    vaccination 183, 281, 282  
  hepatitis B immune globulin 281  
  hepatitis C **182**, 184–189  
    antiretroviral therapy 160  
    exposure of healthcare workers 282  
    HIV and 157–158, 160  
  hepatitis D **182**, 189  
  hepatitis E **182**, 189  
  hepatocellular carcinoma  
    hepatitis B 183  
    hepatitis C 186–187  
  hepatotoxicity, antiretroviral therapy  
    154, 160  
hernia, *see* mesh infection  
herpes B virus, investigations **64**  
herpes simplex, treatment in HIV  
  infection 162  
herpes simplex virus type 1  
  encephalitis 63, **64**, 65  
  mortality 66  
  genital ulcer disease 128–129, 136–137  
  laboratory testing 130  
  reactivation 136–137  
herpes simplex virus type 2  
  condoms and 139  
  genital ulcer disease 128–129, 136–137  
  incidence 127  
  laboratory testing 130  
  reactivation 136–137  
Hib conjugate vaccines 58  
highly active antiretroviral therapy  
  (HAART) 157  
  adherence 159–160  
  drug-drug interactions 158–159  
  methadone and 160–161

- high-profile messengers, antimicrobial stewardship 243
  - Hinchey staging, diverticulitis 274
  - hip, septic arthritis 24
  - histopathology
    - osteomyelitis 32
    - prosthetic joint infection 28
  - histoplasmosis, itraconazole 165
  - HIV, *see* human immunodeficiency virus
  - HIV Prevention Trials Network (HPTN) 052 trial 150
  - HLA typing, antiretroviral therapy 157
  - home treatment
    - cellulitis 15
    - urinary tract infections 119
  - horizontal transmission, genital herpes 137
  - hospital-acquired pneumonia, guidelines 83, 84
  - hospitalization, *see* admission to hospital; length of hospital stay
  - human bites 20
  - human immunodeficiency virus 149–182, *see also* antiretroviral therapy
    - anogenital warts and 139
    - condoms and 139
    - encephalitis 62, 64
    - exposure of healthcare workers 281–282
    - hepatitis C and 186
    - HSV-2 and 136
    - meningitis and 58
    - Pneumocystis jiroveci* pneumonia 155–156
    - primary infection 149–152
    - progression 152
    - synergism with STI 128
    - syphilis with 134–136
    - tuberculosis and 88, 91, 93, 153–155
  - human papillomaviruses 127–128
    - condoms and 140
    - incidence 127
    - virus-like particle vaccines 140
  - hydrogen peroxide, no-touch disinfection 223–224
  - hyperbaric oxygen, necrotizing fasciitis 18
  - hypersensitivity
    - abacavir 157
    - penicillin, neutropenic fever syndrome 261–262
  - hypothermia, surgical site infections 225
- i**
- imaging, *see* computed tomography; radiography; scintigraphy; ultrasound
  - imipenem, urinary tract infections 120
  - immigrants, tuberculosis 88
  - immune globulin
    - hepatitis A 181
    - hepatitis B 281
    - varicella zoster 283
  - immunization, *see* vaccination
  - immunization (passive), *C. difficile* 104
  - immunoassays, *C. difficile* toxins 100
  - immunodeficiency, granulocytic 251–252
  - immunofluorescence assays
    - HIV-1 149
    - influenza 194
  - immunomodulatory therapy, sepsis and 205
  - immunosuppressive therapy (biologic), tuberculosis and 88
  - impetigo 13
  - inactivated influenza vaccine 196–197, 280
  - inactive hepatitis B infection 183
  - inappropriate antimicrobial use 236–237
  - inception cohorts 7
  - incision and drainage, chancroid 137
  - incisional hernia, mesh infection 271–273
  - incisional surgical site infections 224, 269
  - indirect immunofluorescence assay, HIV-1 149
  - induced sputum, *P. jiroveci* pneumonia 155
  - induration, necrotizing fasciitis 16–17
  - infection control 217–236
  - Infectious Diseases Society of America (IDSA)
    - guidelines, prospective audit and feedback 240
    - on neutropenic fever syndrome 258
  - infective endocarditis 37–51
    - central line-associated bloodstream infections 209
    - diagnosis 40, 41
  - inflammatory markers, prosthetic joint surgery 27
  - inflammatory response, septic arthritis 23–24
  - influenza 193–201
    - antigenic types 194
    - diagnosis 195–194
    - encephalitis 64, 65
    - in healthcare workers 279–280
    - neutropenic fever syndrome mimicking 255, 259

inguinal hernia, mesh infection 201, 205  
 injection drug use, infective endocarditis 38  
 insertion bundles, central venous catheters 210  
 insomnia, antiretroviral therapy 158  
 integrase inhibitors, HIV 156, 158, 160  
 integrase strand-transfer inhibitor resistance, HIV 152  
 intensive care units, *see also* critical care  
   community-acquired pneumonia, treatment 76  
   environmental organisms 222–224  
 intention-to-treat population 5  
 interdisciplinary teams, antimicrobial stewardship 243  
 interferon  
   hepatitis B 184  
   hepatitis C 186, 282  
   hepatitis D 189  
 interferon gamma release assays, tuberculosis 90, 93  
 International Collaboration on Endocarditis 44–46  
 intracranial hemorrhage, infective endocarditis 45  
 intracranial pressure, cryptococcal meningitis 165  
 intravenous antibiotics  
   penicillin, syphilis 135  
   urinary tract infections 120  
 intravenous drug use, infective endocarditis 38  
 intravenous fluids, *see* fluid therapy  
 intravenous immunoglobulin, necrotizing fasciitis 17–18, 271  
 intravenous urography, urinary tract infections in men 116  
 irrigation, septic arthritis and 25  
 isoniazid (INH) 91, 92  
   HIV/TB co-infection 153–154  
   latent TB infection 93  
   secondary prophylaxis 91  
 itraconazole  
   cryptococcal meningitis 163–165  
   histoplasmosis 165

## j

Japanese encephalitis virus 62  
 Jarisch-Herxheimer reaction 135  
 JC polyoma virus, investigations 64

joints  
   prostheses, infection 26–30  
   septic arthritis 23–26

## k

kidneys, *see* renal disease  
*Klebsiella granulomatis* 131  
*Klebsiella pneumoniae*, antibiotic-resistant 262–263  
 knee, septic arthritis 24

## l

laboratory testing  
   early HIV 149–150  
   encephalitis 64–65  
   neutropenic fever syndrome 254–255  
   post-operative fever 270  
   sexually transmitted infections 129–131  
   tuberculosis 88–89  
*Lactobacillus* probiotic 103  
 lamivudine (3TC) 156–158  
   hepatitis B 184  
 laparotomy, mesh infection 271–273  
 laryngitis, inappropriate antimicrobial use 237  
 latent TB infection (LTBI) 88, 92–93  
 leadership, antimicrobial stewardship 243  
 ledipasvir 188  
*Legionella pneumophila*  
   antigen testing 75  
   healthcare-associated pneumonia 83  
 length of hospital stay, *see also* duration of treatment  
   healthcare-associated pneumonia 85  
   as outcome measure 239  
 leukemia 251–252  
 leukocyte counts  
   cerebrospinal fluid 65  
   prosthetic joint infection 27  
   septic arthritis 24  
 leukocyte esterase test, urine 108  
 level of consciousness, meningitis 55  
   lumbar puncture 56  
 levofloxacin, urinary tract infections 115, 118  
 likelihood ratios 3–4  
   symptoms of urinary tract infections 108  
 linezolid, healthcare-associated pneumonia 83  
 lipo-arabinomannan, tuberculosis 90

- liposomal amphotericin, cryptococcal meningitis 163
- Listeria monocytogenes*, meningitis 55–57
- live aerosolized influenza vaccine 280
- live attenuated influenza vaccine 197
- liver
  - antiretroviral therapy, HIV 156–157, 160
  - hepatitis B and 184
  - hepatitis C 186–187
- lopinavir/ritonavir 158
- lumbar puncture
  - meningitis 55–56
  - cryptococcal 165
  - syphilis 134, 136
- lymphadenopathy, early HIV 149
- lymphocytic choriomeningitis virus, investigations 64
- lymphogranuloma venereum 129, 130
  - management 137
- m**
- M72/AS01 (tuberculosis vaccine) 94
- macrolides
  - Chlamydia trachomatis* 133
  - Clostridium difficile* and 77
- macroporous mesh 272
- magnetic resonance imaging
  - cerebral
    - encephalitis 65
    - infective endocarditis 44
    - meningitis 56
    - osteomyelitis 32
    - prosthetic joint infection 28
    - septic arthritis 25
- maintenance bundles, central venous catheters 210
- malar rash, erysipelas 14
- MASCC scores 258
- Mastering Hospital Antimicrobial Resistance in ICU trial 221
- matrix-assisted laser desorption/ionization
  - time of flight mass spectrometry, meningitis 57
- measles
  - encephalitis 62, 64
  - post-infectious encephalomyelitis 64, 66
- Medical Research Council, trials of TB treatment 90–91
- men who have sex with men, *see* gay men
- meningitis 53–59
  - broad-range panels, diagnosis 56–57
  - cryptococcal 163–165
  - differential diagnosis 54–55
  - preventive therapy 58–59
  - prognosis 59
- meningococcus, *see* *Neisseria meningitidis*
- meperidine, diverticulitis 275
- meropenem
  - monotherapy 236
  - neutropenia and 260
- mesh infection
  - incisional hernia 271–273
  - inguinal hernia 201, 205
- Metavir scale, liver fibrosis 187
- methadone
  - dolutegravir and 159
  - highly active antiretroviral therapy and 160–161
- methicillin resistant *S. aureus* (MRSA)
  - cellulitis 15–16
  - contact precautions 220–222
  - healthcare-associated pneumonia 82
  - hospital-acquired pneumonia 83
  - ICU environments 222–223
  - impetigo 13
  - mesh infection 273
  - neutropenia and 263
  - septic arthritis 25
  - surgical site infection prevention 228
- methicillin susceptible *S. aureus* (MSSA), necrotizing fasciitis 17
- metronidazole
  - for *Clostridium difficile* 101, 102
  - for trichomoniasis 134
- microbe outcomes, antimicrobial stewardship 237, 239
- microbiologically documented infections (MDI), neutropenic fever 256, 257
- Microscopic Observation Drug Susceptibility, tuberculosis 89
- minocycline, *C. trachomatis* 133
- Modified Duke Criteria, infective endocarditis 40–41
- MODIFY trials, *C. difficile* 104
- molecular tests
  - community-acquired pneumonia 75
  - community-acquired respiratory viruses 257

- drug susceptibility testing,
    - tuberculosis 89–90
  - herpes simplex virus 130
  - monoclonal antibodies, *C. difficile* 104
  - monotherapy, antibiotics, neutropenic fever 236
  - mortality
    - acute myeloid leukemia 251
    - community-acquired pneumonia 74
    - encephalitis 66
    - healthcare-associated pneumonia 84–85
    - hepatitis C 185
    - infective endocarditis 46
    - meningitis 59
    - as outcome measure, antibiotic stewardship **239**
    - sepsis 201, 204
    - tuberculosis 92
    - undertreatment, antibiotic stewardship 236
  - moxifloxacin
    - lymphogranuloma venereum 138
    - with meropenem 236
    - Mycoplasma genitalium* 134
  - mucopurulent cervicitis 132–134
  - multidetector CT angiography, ECG-gated,
    - infective endocarditis 41
  - multidisciplinary interventions, surgical site infections 228
  - multidrug-resistant pathogens
    - contact precautions 220, 221
    - environmental sources 222–224
    - healthcare-associated pneumonia 81–83
    - preventing transmission 217–224
    - prior room occupants 222–223
  - multidrug-resistant TB (MDR-TB) 92, 93, 153–155, *see also* drug-resistant TB epidemiology 87
  - Multinational Association for Supportive Care in Cancer scores 258
  - multiplex PCR
    - influenza 194
    - prosthetic joint infection 28
  - mumps, encephalitis 62, 64
  - mupirocin
    - impetigo 13
    - ointment 227–228
  - mutations, HIV 152
  - MVA85A-IMX313 (tuberculosis vaccine) 94
  - Mycobacterium avium* complex 165–167
    - stopping prophylaxis 166–167
  - Mycobacterium Growth Indicator Tube,
    - tuberculosis 89
  - Mycoplasma genitalium* 131, 133
    - moxifloxacin 134
  - Mycoplasma pneumoniae*, community-associated pneumonia 83
  - mycotic aneurysms 43
- n**
- nafcillin, infective endocarditis **42**
  - NAP1/B1/027 *Clostridium difficile* 99
  - nasal decolonization 227
  - nasopharynx, specimens for influenza 194
  - National Surgical Infection Prevention Collaborative 230
  - neck stiffness, meningitis 55
  - necrotizing fasciitis 16–18
    - post-operative 270–271
  - needle injuries 280–282
  - Neisseria gonorrhoeae*, *see also* gonorrhea
    - condoms and 139
    - laboratory testing 129
    - management 132
    - pelvic inflammatory disease 134
  - Neisseria meningitidis*
    - meningitis 55, **58**, 59
    - polymerase chain reaction, diagnosis 4
  - neonates
    - hand hygiene trial 218–219
    - hepatitis B 183
    - herpes simplex virus 137
  - neuraminidase inhibitors, influenza 195
    - prophylaxis 197, 280
  - neurogenic bladder 115
  - neuropathy, urinary tract infections 112
  - neurosyphilis
    - laboratory testing 131
    - management 135, 136
    - neurorelapse 134
  - neutropenic fever syndrome 251–270
    - monotherapy 236
    - organisms 259
      - antibiotic-resistant 262–263
    - persistent and recrudescant 261
    - scoring system 258
    - sites of infection 257

nitrite test, urine 108  
 nitrofurantoin 111  
 non-gonococcal urethritis 132–134  
 non-nucleoside reverse transcriptase  
   inhibitors HIV 157, 158  
   minority variants 152  
   resistance 151  
 nonoxynol-9, sexually transmitted  
   infections 139  
 non-responders, HBV vaccination 281  
 non-treponemal tests, syphilis 130–131  
 norfloxacin, urinary tract infections 117, 120  
 nosocomial infective endocarditis 38  
 nosocomial meningitis 55, 57, **58**  
 nosocomial pathogens, *see* multidrug-resistant  
   pathogens  
 no-touch disinfection 223–224  
 nuclear imaging, *see* scintigraphy  
 nucleic acid amplification tests (NAAT)  
   *Chlamydia trachomatis* 129–130  
   *Clostridium difficile* 100  
   influenza 194  
   *Neisseria gonorrhoeae* 129  
   *Trichomonas vaginalis* 130  
   tuberculosis 89  
 nucleic acid testing (NAT), HIV 150  
 nucleoside analogs, hepatitis B 184  
 nucleoside reverse transcriptase inhibitors,  
   HIV 156–158  
 nudging interventions, antimicrobial  
   stewardship 242–243  
 number needed to treat 6

## O

occupational exposure (body fluids) 280–282  
 ofloxacin, *Chlamydia trachomatis* 133  
 ombitasvir **188**  
 oral fluid samples, HIV 150  
 organ space infections, surgical 269  
 oropharyngeal decontamination 207  
 orthopedic implants, infection 26–30  
 oseltamivir 195, 280  
 osteitis 31  
 osteomyelitis 30–33  
   diabetes 18  
 otitis media, duration of treatment 236  
 outcome measurement  
   antimicrobial stewardship 237, **239**  
   neutropenic fever syndrome 260–261

outpatients, community-acquired pneumonia  
   treatment 75–76  
 oxacillin, infective endocarditis **42**  
 oxygen  
   SOFA score **202**  
   surgical site infections and 225–226, 230

## P

*p* values 6  
 PaLoc (pathogenicity locus), *C. difficile* 100  
 paritaprevir **188**  
 partners, treatment for sexually transmitted  
   infections 137, 139  
 passive smoking, tuberculosis 88  
 pathogenicity locus (PaLoc), *C. difficile* 100  
 PEACH trial, pelvic inflammatory  
   disease 134  
 peer comparison, antimicrobial  
   stewardship 243  
 pegylated interferons, hepatitis C and 282  
 pelvic inflammatory disease 128, 134  
 penicillin  
   allergy, neutropenic fever syndrome  
     261–262  
   impetigo 13  
   necrotizing fasciitis 17  
 penicillin G  
   infective endocarditis **42**  
   syphilis 135  
 pentamidine  
   *Pneumocystis jiroveci* pneumonia  
     155, 161  
   toxoplasmosis prophylaxis 162  
 peramivir 195  
 peri-operative prophylaxis,  
   antibiotics 228–230  
 peri-operative warming 225, 230  
 periprosthetic tissue cultures 28  
 peritonitis, diverticulitis 274  
 personal protective equipment 220  
 physical examination, neutropenic fever  
   syndrome 254, **255**  
 PICO (posing a clinical question) 2–3  
 piperacillin/tazobactam, urinary tract  
   infections 120  
 plasmid-based resistance genes, *E. coli*  
   ST131 110  
 platelet counts, SOFA score, sepsis **202**  
 pleconaril 66

- pleocytosis
  - encephalitis 64
  - meningitis 56
- pneumococcal antigen, urine 75
- pneumococcal polysaccharide
  - vaccine 58–59, 77–78
- pneumococcal protein conjugate vaccine 59
- Pneumocystis jiroveci* pneumonia
  - (PCP) 155–156
  - prophylaxis 161
  - stopping 162
- pneumonia, *see also Pneumocystis jiroveci* pneumonia
  - community-acquired 73–80
  - evidence base for treatment 2
  - healthcare-associated 81–86
  - influenza, radiography 194
  - neutropenia 254
  - ventilator-associated 205–207
    - healthcare-associated pneumonia *vs* 81–82
    - monotherapy 236
- podophyllotoxin 138
- point-of-care testing
  - HIV 150
  - sexually transmitted infections 131–132
- polymerase chain reaction
  - community-acquired pneumonia 75
  - encephalitis 64, 65
  - herpes simplex virus 130
  - infective endocarditis 39
  - influenza 194
  - meningitis 56–57
  - multiplex
    - influenza 194
    - prosthetic joint infection 28
  - Neisseria meningitidis* 4
  - Pneumocystis jiroveci* pneumonia 155
  - progressive multifocal
    - leukoencephalopathy 167–168
  - sexually transmitted infections 129–130
  - syphilis 131
- polymorphonuclear cells, meningitis 56
- polyphenon E, genital warts 138
- polysaccharide vaccine,
  - pneumococcal 58–59, 77–78
- positioning of patient, on ventilators 207
- postcoital prophylaxis, urinary tract
  - infections 114–115
- post-exposure prophylaxis
  - human immunodeficiency virus 281
  - varicella zoster virus 283
- post-gonococcal urethritis 132–134
- post-infectious disseminated
  - encephalomyelitis 62
- post-infectious encephalomyelitis,
  - measles 64, 66
- post-interventional septic arthritis 24
- post-operative antibiotics 229
- post-operative infections 224–230, 269–270
  - mesh infection 201, 205, 271–273
- post-prescription review, antimicrobial
  - stewardship 241–242
- povidone-iodine, central venous
  - catheters 209
- Powassan virus, encephalitis 62
- preauthorization, antimicrobial
  - stewardship 241–242
- predictive values 3
- pre-emptive short course treatment, urinary
  - tract infections 114–115
- pregnancy
  - asymptomatic bacteriuria 113
  - Chlamydia trachomatis* 133
  - hepatitis B 183
  - herpes simplex virus 137
  - influenza 196
  - sexually transmitted infections 128
  - syphilis
    - antibiotics 135
    - Jarisch-Herxheimer reaction 135
  - urinary tract infections, antibiotics 111
  - varicella zoster immune globulin 283
- pre-placement immunity, varicella zoster
  - virus 283
- prescribing behavior, interventions
  - on 239–243
- prescribing practice 235–237
  - urinary tract infections 111
- pre-treatment/transmitted drug resistance,
  - HIV 151
- prevalence, predictive values and 3
- primaquine, *P. jiroveci* pneumonia 156
- primary infection
  - herpes simplex virus 136
  - HIV 149–152
- primary prophylaxis, *C. difficile* 103
- probabilities 3

- probiotics
    - Clostridium difficile* infection 103, 104
    - urinary tract infections 115
  - procalcitonin 77
  - process measures, antimicrobial
    - stewardship 237
  - proctitis 129
    - lymphogranuloma venereum,
      - azithromycin 137
  - progressive multifocal leukoencephalopathy 167–168
  - promotional campaigns, influenza
    - vaccination 280
  - prophylaxis, *see also* infection control;
    - post-exposure prophylaxis;
      - vaccination
    - antibiotics, animal bites 20
    - Clostridium difficile* 103–104
    - hepatitis B reactivation 183–184
    - hepatitis C 189
    - infective endocarditis 46, 47
    - influenza 196–197, 280
    - isoniazid (INH) 91
    - Mycobacterium avium* complex,
      - stopping 166–167
    - opportunistic infections, HIV 161–162
    - peri-operative, antibiotics 228–230
    - toxoplasmosis 162–163
    - tuberculosis, HIV-positive patients 154
    - urinary tract infections 114–115
    - ventilator-associated pneumonia 207
  - prospective audit and feedback, on
    - prescribing behavior
      - 239–240, 242
  - prostatitis 116–118
  - prosthetic joint infection 26–30
    - exchange of prosthesis 29
    - granulocyte count, diagnosis 27
  - prosthetic valve infective endocarditis
    - antibiotics 42, 47
    - organisms 38
  - protease inhibitors 156, 158, 159
    - hepatitis C 187
  - protein, cerebrospinal fluid 56, 65
  - prozone phenomenon, syphilis 131
  - pseudomembranous colitis 100
  - Pseudomonas* (spp.)
    - antibiotics for 83
    - healthcare-associated pneumonia 82
  - Pseudomonas aeruginosa*
    - antibiotic-resistant 262
    - ventilator-associated pneumonia 207
  - PSI score, community-acquired
    - pneumonia 74
  - psychiatric illness, antiretroviral therapy 158
  - psychological effects, contact
    - precautions 221
  - pulmonary artery catheterization,
    - sepsis 203
  - punch injury 19
  - purulent rhinitis, inappropriate antimicrobial
    - use 236–237
  - pyelonephritis 118, 119
    - ciprofloxacin, duration of treatment 236
  - pyrazinamide 91
    - HIV/TB co-infection 153–154
  - pyrimethamine
    - Pneumocystis jiroveci* prophylaxis 161
    - toxoplasmosis prophylaxis 162
  - pyuria 108
    - men 116
    - quantitation 118
- q**
- quasi-experimental studies
    - antimicrobial stewardship 238, 242
    - surgical site infections 228
  - quaternary ammonium, no-touch disinfection
    - vs* 224
  - questions, clinical 2–3
- r**
- rabies
    - animal bites 20, 62–63
    - clinical presentation 63
    - immunization 66
    - investigations 64
  - radiography
    - cellulitis 15
    - community-acquired pneumonia 73–74
    - diverticulitis 275
    - influenza 194
    - osteomyelitis 32
    - Pneumocystis jiroveci* pneumonia 155
    - prosthetic joint infection 28–29
    - septic arthritis 24–25
    - tuberculosis 90
    - urinary tract infections and 110

- radionuclide imaging, *see* scintigraphy
  - raltegravir 156, 158, 281
  - randomization 5, *see also* cluster randomization
  - randomized controlled trials 4–7
    - history 1
  - rapid antigen tests, influenza 194
  - rapid plasma reagin test, syphilis 131
  - rapid point-of-care testing, HIV 150
  - rash, meningitis 55
  - reactivation
    - hepatitis B 183–184, 187–189
    - herpes simplex virus 136–137
  - real time PCR, prosthetic joint infection 28
  - recombinant DNA HBV vaccines 281
  - recommendations, strength of 6–8
  - recrudescent neutropenic fever syndrome 261
  - recurrent cellulitis 16
  - recurrent *Clostridium difficile* infection 99, 102, **103**
    - antibiotics for 101, **103**
    - fidaxomicin 102
    - monoclonal antibodies 104
  - recurrent urinary tract infections 114–115
    - men 117
  - red blood cells, CSF, encephalitis 65
  - REDUCE-MRSA trial 221
  - reference standards 4
  - refugees, tuberculosis 88
  - reinfection
    - infective endocarditis 46
    - sexually transmitted infections, prevention 139
    - urinary tract 114
  - relapse
    - infective endocarditis 46
    - urinary tract infections 120
  - relative risk 5
  - renal disease
    - antiretroviral therapy 157
    - hepatitis C 186
  - resection of colon, diverticulitis 276
  - respiratory specimens, tuberculosis 88
  - respiratory tract infections, *see also* pneumonia
    - inappropriate antimicrobial use 236–237
    - neutropenia 255
  - response to treatment
    - neutropenic fever syndrome 260–261
    - urinary tract infections 120, 121
  - restrictive strategies, antimicrobial stewardship 241–242
  - resuscitation, sepsis 203
  - retapamulin, impetigo 13
  - retinitis, cytomegalovirus infection 167
  - rheumatoid arthritis, septic arthritis 24
  - rhinitis, inappropriate antimicrobial use 236–237
  - ribavirin 186, 187, **188**, 282
  - rifabutin, *Mycobacterium avium* complex 166
  - rifampicin (RIF) 91
    - HIV/TB co-infection 153–154
    - latent TB infection 93
    - resistance, gene sequencing 153
  - rifampin, prosthetic joint infection 30
  - rilpivirine 156, 158
  - risk
    - assessment, febrile neutropenic episodes 257–258
    - reduction 6
    - relative 5
  - ritonavir 156, 158, **188**
  - rituximab, hepatitis B and 184
  - Rivers trial (2001) 203
  - RNA testing, HIV 150
  - rpoB* gene sequencing 153
  - rRNA, meningitis 57
- S**
- Sackett, David, definition of evidence-based medicine 1
  - same-day sputum collection, tuberculosis 88
  - scintigraphy
    - osteomyelitis 32
    - prosthetic joint infection 28
    - septic arthritis 25
  - screening
    - hepatitis B 183
    - hepatitis C 185
    - latent TB infection 93
    - methicillin resistant *S. aureus* 228
    - sexually transmitted infections 129, 130
  - seasonal variation, viral encephalitis 61–62
  - secondary prophylaxis
    - Clostridium difficile* 104
    - isoniazid (INH) 91

- second-hand smoke exposure,
  - tuberculosis 88
- seeding
  - septic arthritis, *see* hematogenous seeding
- self-directed therapy, urinary tract
  - infections 115
- Semmelweis, Ignaz 218
- sensitivity (of tests) 3, 4
- sepsis 118, 201–205
  - duration of treatment 236
  - monotherapy 236
  - neutropenia 252–258
- septic arthritis 23–26
- septic shock 202
  - antibiotics 204
  - resuscitation 203
- sequential organ failure assessment 202
- sequential regimens, *C. difficile* 102
- serofast state, syphilis 135
- serology
  - syphilis 130–131
  - tuberculosis 90
- severe *Clostridium difficile* infection 99
- sexual activity, urinary tract infections 114
- sexually transmitted infections 127–149,
  - see also* human immunodeficiency virus
  - diagnosis 128–132
  - laboratory testing 129–131
  - management 132–139
  - prevention 139–140
- sharp injuries 280–282
- shaving, surgical site infections and 226
- short course treatment 236
  - tuberculosis 91
  - urinary tract infections, pre-emptive 114–115
- sigmoid colon, resection, diverticulitis 276
- SINGLE study, antiretroviral therapy 158
- SIRS criteria 15
- skin diseases
  - hepatitis C 186
  - infectious 13–22
- smear examination
  - sputum 89
  - Tzank smear 130
- smoking
  - surgical site infections and 226–227
  - tuberculosis 88
- social norm feedback, antimicrobial
  - stewardship 243
- SOFA, quick 202
- sofosbuvir 187, **188**, 282
- sonication, prosthetic joints 28
- source control, sepsis 204–205
- spacers, prosthetic joint infection 29
- specificity (of tests) 3, 4
- specimens
  - influenza 194
  - tuberculosis 88
  - ventilator-associated pneumonia 206
- spectinomycin, chancroid 137
- spermicides
  - sexually transmitted infections and 139
  - urinary tract infections 114
- spinal cord injury, urinary tract
  - infections 115, 120
- splenomegaly, infective endocarditis 38
- SPRING-2 study, antiretroviral therapy 158
- sputum
  - community-acquired pneumonia 75
  - Pneumocystis jiroveci* pneumonia 155
  - tuberculosis 88, 89, 153
- squamous cell carcinoma, genital warts 139
- ST131 strain, *Escherichia coli* 110
- staffing, antimicrobial stewardship 243
- Staphylococcus* (spp.)
  - central line-associated bloodstream
    - infections 209
  - furuncles 14
  - impetigo 13
  - infective endocarditis 38, **42**, 43
  - meningitis **58**
  - osteomyelitis 33
  - prosthetic joint infection 30
- Staphylococcus aureus*, *see also* methicillin
  - resistant *S. aureus*
    - central line-associated bloodstream
      - infections 209
    - elimination from surgical sites 227–228
    - hand contamination 218–219
    - healthcare-associated pneumonia 82
    - mesh infection 272–273
    - necrotizing fasciitis 17
    - septic arthritis 24
    - ventilator-associated pneumonia 206
- Staphylococcus saprophyticus*, urinary tract
  - infections 110

- statistical significance 6
  - sterile technique, central venous catheters 209
  - steroids, *see* corticosteroids
  - stewardship personnel 240
  - STOP-IT trial, antimicrobial stewardship 236
  - strand displacement amplification (NAAT), sexually transmitted infections 129–130
  - Strategic Timing of Antiretroviral Treatment Trial 150–151
  - Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units trial 220
  - strength of recommendations 6–8
  - streptococcal impetigo 13
  - streptococcal toxic shock syndrome 271
  - Streptococcus* (spp.)
    - group A, necrotizing fasciitis 16, 17–18, 271
    - prosthetic joint infection 30
    - viridans group, infective endocarditis 38, 42
  - Streptococcus agalactiae*, meningitis 55
  - Streptococcus gallolyticus*, infective endocarditis 42
  - Streptococcus pneumoniae*
    - community-acquired pneumonia 75
    - healthcare-associated pneumonia 82, 83
    - meningitis 55, 57, 58
    - preventive therapy 58–59
  - stroke, infective endocarditis 43–45
  - students, education on antimicrobial stewardship 241
  - subacute sclerosing panencephalitis 62, 64
    - electroencephalography 65
  - subclavian lines, bloodstream infections 209
  - subclinical shedding, herpes simplex virus 136
  - subglottic drainage, endotracheal tubes 207
  - sub-Saharan Africa, *P. falciparum* prophylaxis 161
  - sulfamethoxazole, *see* trimethoprim/sulfamethoxazole
  - sulfanilamide-allantoin-aminacrine, trichomoniasis and 134
  - surgery, *see also* prosthetic joint infection
    - for infective endocarditis 44–45
    - necrotizing fasciitis 270–271
    - for osteomyelitis 32
    - site infections 224–230, 269–270
      - mesh infection 201, 205, 271–273
    - wound classification 228–229
  - Surgical Care Improvement Project 230
  - surveillance, contact precautions 221, 222
  - sustained virologic response, hepatitis C 186
  - syndromic diagnosis, sexually transmitted infections 128–129
  - syndromic management, sexually transmitted infections 132
  - synovial fluid
    - prosthetic joint infection 27
    - septic arthritis 24, 26
  - syphilis
    - chancre 129
    - condoms and 139
    - enzyme immunoassay, treponemal 131
    - incidence 127
    - laboratory testing 130–131
    - management 134–135
    - treatment of partners 139
  - systematic reviews 3, 6
  - systemic inflammatory response syndrome 201–202
    - criteria 15
    - febrile neutropenia 254, 257–258
- t**
- tamsulosin, prostatitis 118
  - tapering regimens, *C. difficile* 102
  - tcdC* gene, *C. difficile* 99
  - temperature (core), in surgery 225
  - temporal lobe, encephalitis 65
  - tenofovir (TDF)
    - hepatitis B 183
    - prodrugs 184
    - HIV 157, 158
      - BHIVA guidelines 156
      - post-exposure prophylaxis 281
      - resistance 151
  - tetracyclines
    - Chlamydia trachomatis* 133
    - syphilis 135
  - text messaging interventions, ART adherence 159
  - therapeutic drug monitoring, ART 159
  - tigecycline 101

- time-to-defervescence, neutropenic fever syndrome 260–261
  - time-to-first-dose, neutropenic fever syndrome 256
  - timing, antibiotics for surgery **229**
  - tinidazole, trichomoniasis 134, 139
  - tissue cultures, periprosthetic 28
  - tolevamer 101
  - topical therapy
    - genital herpes 136
    - trichomoniasis and 134
  - toxigenic culture, *Clostridium difficile* 100
  - toxin, *Clostridium difficile* 100
    - monoclonal antibodies 104
    - tests for 100
  - toxoplasmosis prophylaxis, HIV 162–163
  - tracheal aspiration, *see also* subglottic drainage
    - ventilator-associated pneumonia 206
  - transaminases, antiretroviral therapy 160
  - transesophageal echocardiography, infective endocarditis 39
  - transmission, *see also* infection control
    - genital herpes 136
    - influenza 197
  - transmission-mediated amplification (NAAT), STI 129–130
  - transmitted drug resistance, HIV 151
  - treponemal tests, syphilis 131
  - Treponema pallidum* particle agglutination (TP-PA) test 131
  - triage, neutropenic fever syndrome 253, 254
  - trichomoniasis 128
    - incidence 127
    - laboratory testing 130
    - management 134
    - treatment of partners 139
  - trimethoprim, urinary tract infections 108
  - trimethoprim/sulfamethoxazole (TMP/SMX)
    - granuloma inguinale 138
    - HIV/TB co-infection 91
    - impetigo 13
    - Pneumocystis jiroveci* pneumonia 155, 161, 162
    - resistance 120–121
    - toxoplasmosis prophylaxis 162
    - urinary tract infections 111, 112
      - men 117
      - preventive therapy 115
  - trimetrexate, *P. jiroveci* pneumonia 156
  - trivalent inactivated influenza vaccine 196–197
  - tuberculin skin test 92–93
    - HIV-positive patients 154
  - tuberculosis 87–97
    - HIV and 153–155
    - risk factors 88
    - two-day sputum collection 88
- U**
- ulcers, *see also* genital ulcer disease
    - diabetes 18–19
  - ultrasound
    - echocardiography, infective endocarditis 39
    - Fibrosan 187
    - prosthetic joint infection 28
    - urinary tract infections in men 116
  - ultraviolet light, no-touch disinfection 223–224
  - undertreatment, antimicrobial stewardship 235, 236
  - universal chlorhexidine body washing 221
  - unnecessary treatment, antibiotics 109, 235–236
  - upper airways, colonization, VAP 206
  - urethritis, non-gonococcal 132–134
  - urinary tract infections 107–126
    - men 115–118
    - prognosis 112–113
    - severe and complex 118–121
    - treatment without tests 109
    - women 107–115, 119
  - urine
    - alkalization 112
    - contamination 109
    - dipstick testing 107–109, 118
    - microscopy 108
    - pneumococcal antigen 75
  - utilization measures, antimicrobial 237, **239**
- V**
- vaccination
    - community-acquired pneumonia 77–78
    - encephalitis 66
    - hepatitis A 181
    - hepatitis B 183, 281, 282
    - Hib meningitis 58
    - influenza 196–197, 280

- meningitis 55, 58–59
  - sexually transmitted infections 140
  - Streptococcus pneumoniae* 58–59
  - tuberculosis 93–94
  - varicella zoster virus 283
  - vaginal discharge **108**, 128
  - vaginal irritation **108**
  - vaginal swabs 130
  - valacyclovir
    - encephalitis 65
    - genital herpes 136, 137
    - orolabial herpes 162
  - valganciclovir, CMV infection 167
  - valve surgery, *see also* prosthetic valve infective endocarditis
    - for infective endocarditis 44–45
  - vancomycin
    - central line-associated bloodstream infections 208–209
    - for *Clostridium difficile* 101, 102, **103**, 104
    - infective endocarditis **42**
    - meningitis **58**
    - methicillin resistant *S. aureus* and 263
    - neutropenic fever syndrome 259–260
    - septic arthritis 25
    - surgical site infection prevention 228
  - vancomycin-resistant *Enterococcus* (VRE)
    - contact precautions 220, 222
    - hand contamination 218
    - ICU environments 222–223
    - after stem cell transplant 263
  - varicella zoster immune globulin 283
  - varicella zoster virus
    - encephalitis 63, **64**
    - exposure of healthcare workers 282–284
  - velpatasvir 187, **188**
  - Venereal Disease Research Laboratory (VDRL) test, syphilis 131
  - ventilator-associated pneumonia 205–207
    - diagnosis, tracheal aspiration 206
    - healthcare-associated pneumonia
      - vs 81–82
    - monotherapy 236
  - vertical transmission, genital herpes 137
  - Vibrio vulnificus* 14, 271
    - antibiotics 17
  - viral load, on HIV outcome 152
  - viridans group streptococci, infective endocarditis 38, **42**
  - virulence genes, *E. coli* ST131 110
  - viruses
    - community-acquired pneumonia 75
    - encephalitis 61–66
    - meningitis, PCR 57
    - neutropenic fever syndrome 257
  - virus-like particle vaccines, human papillomaviruses 140
  - visual inspection, assessment of cleaning 223
- W**
- warming, peri-operative 225, 230
  - warts, genital 138–139
  - water, organisms causing cellulitis 14
  - weight loss, early HIV 149
  - West Nile virus 62, 63, **64**, 65
  - western blot, HIV-1 149
  - wet mount, *Trichomonas vaginalis* 130
  - whole genome sequencing
    - meningitis 57
    - tuberculosis 90
  - World Health Organization, hand hygiene studies 219
  - wounds, classification for antibiotic prophylaxis 228–229
- X**
- X-linked agammaglobulinemia, enteroviral encephalitis 65–66
  - Xpert MTB/RIF test 89, 153
- Z**
- zanamivir 195, 280
  - zidovudine (AZT) 157
    - post-exposure prophylaxis 281
  - Zika virus 62